Literature DB >> 1379827

High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants.

M Wall1, S Southwood, J Sidney, C Oseroff, M F del Guericio, A G Lamont, S M Colón, T Arrhenius, F C Gaeta, A Sette.   

Abstract

A direct binding assay specific for IAs molecules has been developed and its immunological relevance validated by examining, for a panel of nine different synthetic peptides, the correlation between their capacity to bind purified IAs and to inhibit IAs-restricted antigen presentation. The IAs assay thus developed has then been used to study the IAs binding affinity of a set of overlapping peptides spanning the entire myelin basic protein (MBP). It was found that the encephalitogenic MBP region corresponds to peptides with high MHC binding affinities. Other regions of the MBP that have not been described as being pathogenic in the context of IAs molecules have also been found to be high IAs binders, suggesting that variables other than MHC affinity are also involved in determining the pathogenic potential of self-derived determinants.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379827     DOI: 10.1093/intimm/4.7.773

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  15 in total

Review 1.  Unusual features of self-peptide/MHC binding by autoimmune T cell receptors.

Authors:  Melissa J Nicholson; Michael Hahn; Kai W Wucherpfennig
Journal:  Immunity       Date:  2005-10       Impact factor: 31.745

2.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Short-lived complexes between myelin basic protein peptides and IAk.

Authors:  K Mason; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

4.  A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11.

Authors:  C I Pearson; A M Gautam; I C Rulifson; R S Liblau; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

5.  Quantitative analysis of peptides from myelin basic protein binding to the MHC class II protein, I-Au, which confers susceptibility to experimental allergic encephalomyelitis.

Authors:  L Fugger; J Liang; A Gautam; J B Rothbard; H O McDevitt
Journal:  Mol Med       Date:  1996-03       Impact factor: 6.354

6.  Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA.

Authors:  Hiroko Miyadera; Jun Ohashi; Åke Lernmark; Toshio Kitamura; Katsushi Tokunaga
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

Review 7.  Associations of human leukocyte antigens with autoimmune diseases: challenges in identifying the mechanism.

Authors:  Hiroko Miyadera; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2015-08-20       Impact factor: 3.172

8.  Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells.

Authors:  V Kumar; V Bhardwaj; L Soares; J Alexander; A Sette; E Sercarz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

9.  Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.

Authors:  J L Dzuris; J Sidney; H Horton; R Correa; D Carter; R W Chesnut; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

Authors:  M Fridkis-Hareli; D Teitelbaum; E Gurevich; I Pecht; C Brautbar; O J Kwon; T Brenner; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.